This suggests that tumor-specific T cells, limited by tumor cell expression of PD-L1 may exist in greater numbers in B16-F10 tumors, explaining why PD-1 blockade was more successful in B16-F10 and CTLA-4 blockade in CT26LacZ models. The gene discussed is CTLA4; the disease is neoplasm.